Viewing nowLyrica Capsule 150mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Korea Hyuntex Pharmaceutical Co., Ltd.

MFDS item code 201600254 · Approved 2016.01.14 · Insurance code 649102950
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, and treatment of fibromyalgia
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct in patients with epilepsy experiencing partial seizures, particularly when these are accompanied by secondary generalization or not. It is helpful in alleviating pain in fibromyalgia patients. This medication is effective for various neurological diseases and pain conditions, and it is used to improve the patient's symptoms.
Administer the total daily dose of this medicine, pregabalin, orally in 2 divided doses, with or without food. Peripheral neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy: Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies were also conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose TID = Divide the total daily dose into 3 doses BID = Divide the total daily dose into 2 doses QD = Administer once daily The total daily dose (mg/day) should be divided as specified in the administration regimen. The supplemental dose refers to an additional dose administered as a single dose. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. No dosage adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years and adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behavior, so careful monitoring for signs of depression, mood changes, or unusual behavior is necessary during use. Do not take this medication if you have hypersensitivity to any of its components or if you have certain genetic lactose metabolism disorders. Diabetic patients should be cautious as weight gain may require adjustment of diabetes control medications. If severe allergic reactions such as angioedema occur, discontinue use immediately. Elderly patients should be careful as there is a risk of falling due to dizziness or drowsiness caused by this medication. Temporary blurred vision or changes in vision may occur, and if such symptoms arise, consult a physician. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be gradually reduced as directed by a physician. Patients with a history of substance abuse may have a higher risk of misuse with this medication, so special caution is advised during use. Patients with poor cardiac or renal function should consult with a doctor before taking this medication, as dose adjustments may be necessary. Taking this medication with opioid analgesics can increase the risk of central nervous system depression, so caution is advised. Pregnant women should avoid use during early pregnancy as it may affect the fetus, and women of childbearing age should use effective contraceptive methods. Nursing mothers should consult with a physician about the possibility of this medication passing into breast milk and whether to discontinue nursing or the medication. Before driving or operating hazardous machinery, check if this medication causes drowsiness or dizziness, and avoid such activities if symptoms are present. In case of overdose, symptoms such as drowsiness, confusion, and depression may appear, and blood dialysis may be necessary as needed.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is recommended to keep it at room temperature between 15 and 30 degrees Celsius.
A hard capsule with a white body and cap containing a white powder that is white or light yellow in color.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Korea Hyuntex Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.